Regeneron Pharmaceuticals awarded Amy Peterson, MD, MS, professor, Division of Cardiology, and co-investigator, Robert Steiner, MD, professor, Division of Genetics and Metabolism, $867,984 for their project, “Opportunity to Reach Individuals with Genetic dyslipidemia during Infancy and the Newborn period to find Familial Hypercholesterolemia (ORIGIN-FH).” The primary objective of this investigator-initiated study is to prospectively screen high risk newborns for homozygous familial hypercholesterolemia (HoFH) and heterozygous familial hypercholesterolemia (HeFH). Familial hypercholesterolemia (FH) is a disorder of lipoprotein metabolism, with affected individuals having lifelong markedly elevated low-density lipoprotein cholesterol (LDL-C) that puts them at high risk for premature atherosclerotic cardiovascular disease (ASCVD). FH is profoundly underdiagnosed; less than 10% of affected adults and 5% of children are identified worldwide. This three-year project began in December 2025 and will end in December 2028.